Pfizer Buys Metsera: Big Pharma's Weight-Loss Play

Pfizer just dropped almost five billion dollars to buy Metsera, a weight-loss drug company, signaling a major power play in the booming obesity treatment market. This acquisition could fast-track Pfizer's entry into the competitive weight-loss arena, putting them head-to-head with other pharmaceutical giants. Will this deal give Pfizer the edge it needs to dominate the future of weight-loss medication? Hosted on Acast. See acast.com/privacy for more information.